News

AB-Therapeutics participates in the 10th Venture Capital Forum NEOTEC

AB-Therapeutics, located at the UAB Research Park, will have the opportunity to meet investors and secure funding for the development of new drugs for the treatment of lung cancer and pancreatic cancer.

The 10 th NEOTEC Venture Capital Forum is a forum where investors and technology companies in funding rounds meet. AB-Therapeutics has been one of the 15 companies selected to participate in this forum, where they will have the opportunity to present their project to potential investors.


AB-Therapeutics is seeking investors for its first round of funding. 85% of the funds will be invested in the preclinical and clinical development of drug candidates to treat lung cancer and pancreatic cancer, through outsourcing to contract research organizationa (CRO). Only 15% of the costs will be allocated to overhead and human resources.

The spin-off  has a new therapeutic approach for cancer of the lung and pancreas, Multitarget Lipid Signaling, which alters the dynamics of multiple proteins in the cell membrane and has a much lower toxicity compared to classical chemotherapy.

NEOTEC Venture Capital Forum will be held on November 10 in La Rioja, organized by the Center for Industrial Technological Development (CDTI), the Economic Development Agency of La Rioja and RedOTRI, and collaboration, among others, ACC1Ó and the Association of Technology Parks of Spain (APTE).

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits